TLR9 and neoplasm: For example, the s.c. administration of gelatin NPs (272 nm) cationized by quaternary amino groups to electrostatically load CpG oligonucleotides, a Toll-like receptor 9 (TLR9) ligand, led to their selective accumulation in dLNs over the spleen, resulting in the efficient activation of CpG-positive DCs in LNs, suppression of tumor growth, and prevention of splenic follicle destruction [85].